Holen Sie sich die Stockscreener-App
59.87
0.12%
-0.07
Handel nachbörslich:
59.87
Schlusskurs vom Vortag:
$59.94
Offen:
$59.94
24-Stunden-Volumen:
1.94M
Relative Volume:
0.74
Marktkapitalisierung:
$11.50B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
22.26
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+2.99%
1M Leistung:
+8.46%
6M Leistung:
+2.69%
1J Leistung:
-7.06%
1-Tages-Spanne:
$59.45
$60.99
1-Wochen-Bereich:
$57.32
$61.48
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.87 | 11.52B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
LSV Asset Management Purchases 812,284 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
New York Life Investment Management LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Baird maintains BioMarin stock rating amid competitor’s positive trial data By Investing.com - Investing.com Nigeria
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights
BioMarin Raises $850 Million Notes for Amicus Acquisition - TipRanks
BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView
BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com UK
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
Pharma companies left out of Trump's drug-pricing deals look for way in - marketscreener.com
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Why BioMarin Pharmaceutical Inc. stock is a must watch in 2025Trade Exit Summary & Verified Momentum Watchlists - mfd.ru
Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia - marketscreener.com
BioMarin receives Health Canada Notice of Compliance with conditions for VOXZOGO®, for Achondroplasia - Newswire Canada
BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is BioMarin Pharmaceutical (BMRN) Now Trading Below Its Long Term Prospects - Sahm
Will BioMarin Pharmaceutical Inc. stock maintain growth storyJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Acquisition plans to fuel BioMarin Pharmaceutical (BMRN), according to Barclays - MSN
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? - Finviz
BioMarin Pharmaceutical Stock Outlook Looks Promising - Intellectia AI
BioMarin’s Strategic Acquisition Nears Critical Data Readout - AD HOC NEWS
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays - Finviz
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum - Sahm
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $84.00 at Piper Sandler - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Achondroplasia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - Barchart.com
AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo - Bloomberg Law News
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Mediolanum International Funds Ltd - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook on a Biotech Leader with 60% Upside Potential - DirectorsTalk Interviews
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
(BMRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc. - MarketBeat
Investors Holding Back On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Should You Buy BioMarin Pharmaceutical Before Feb. 18? - Finviz
BioMarin prices $850 million in senior notes to fund Amicus acquisition - Investing.com India
BioMarin Secures Major Debt Financing for Amicus Acquisition - TipRanks
BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication - TradingView
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):